

## Advanced Immuno-Oncology (I-O) ChangeMakers

### Action Learning Projects to Improve Cancer Care

<b>Project Title</b>	<b>Providing current PD-L1 testing requirements for common cancers</b>
<b>Problem/Challenge</b>	Oncologists and pathologists often have trouble keeping up with the rapid advances in I-O and other biomarker testing requirements for different cancers. As a result, the right biomarkers may not get ordered at the time of diagnosis, and this may delay treatment decisions.
<b>Aim/Goal</b>	Create a point-of-care resource that provides quick information about PD-L1 testing requirements for common cancers. This resource will be referenced by pathologists when a new patient is diagnosed with cancer. This will allow pathologists to know if PD-L1 testing may be required.
<b>Key Interventions</b>	Our team of pathologists reviewed NCCN guidelines for common cancers and created a table that provides the following information for each tumor type: <ol style="list-style-type: none"> <li>1. PD-L1 IHC requirement</li> <li>2. Current process for in-house testing vs. send-out testing</li> <li>3. Approved checkpoint inhibitors and indications</li> <li>4. Antibody clones used for testing</li> </ol> The team has also been working to update these tables by incorporating other targetable biomarkers.
<b>Summary of Results</b>	These cancer biomarker tables have helped our pathologists know when to perform the right PD-L1 test for different cancers at the time of diagnosis. These tables have reduced delays in PD-L1 testing and have reduced confusion regarding different antibody clones. Our team has assigned responsibilities and developed tasks to update these tables twice each year. Some notable updates have included changing requirements in PD-L1 testing for triple negative breast cancer and NSCLC. We currently perform PD-L1 testing in-house for certain types of tumors, so other tumors are sent out to reference labs. These tables have helped us manage and coordinate which tests are performed in-house vs. which are sent out. We have also started to expand these tables to include other biomarkers for certain tumors and we plan to update the tables more frequently.
<b>Project Team/Affiliation</b>	Geunyoung Jung, MD Mark Sharobim, MD, MSc Wei Zhang, MD, PhD University of Wisconsin Madison